Bartsch H H, Pfizenmaier K, Schroeder M, Nagel G A
Department of Internal Medicine, University of Goettingen, F.R.G.
Eur J Cancer Clin Oncol. 1989 Feb;25(2):287-91. doi: 10.1016/0277-5379(89)90021-7.
Fourteen patients with different advanced solid tumors were treated by intratumoral application of recombinant human tumor necrosis factor alpha. In five patients, local tumor regression occurred. However, the duration of response was short, implying a rapid development of resistance to rTNF-alpha application. The main clinical side-effects, including chills, fever, anorexia and fatigue, were similar to systemic rTNF-alpha treatment. Cardiovascular, pulmonary or metabolic toxicities were not observed. This study demonstrates that a high concentration of rTNF-alpha at the tumor site has the potential to induce local tumor regressions and, therefore, seems more reasonable for further clinical investigations, especially in combination with other cytokines.
14例患有不同晚期实体瘤的患者接受了瘤内注射重组人肿瘤坏死因子α的治疗。5例患者出现了局部肿瘤消退。然而，缓解持续时间较短，这意味着对rTNF-α治疗迅速产生了耐药性。主要的临床副作用，包括寒战、发热、厌食和疲劳，与全身性rTNF-α治疗相似。未观察到心血管、肺部或代谢毒性。这项研究表明，肿瘤部位高浓度的rTNF-α有诱导局部肿瘤消退的潜力，因此，似乎更适合进一步的临床研究，特别是与其他细胞因子联合使用时。
